Cobenfy, Clozapine, and Catatonia: A Complex Relationship

Population Pharmacokinetics of Paliperidone Palmitate 351 mg as Alternative Maintenance Dosing

Differentiating Bipolar Spectrum Disorders From Other Psychiatric Disorders With Shared Features

What's Next for PPD Treatment | Inhaled Mebufotenin (GH001) Phase 2a Results

TMS for MDD: What Works, How It Works, and What's Next

Vagus Nerve Stimulation and Suicidal Ideation in Treatment-Resistant Depression | RECOVER Study

Hallucinogen–Psychosis Associations Are Confounded by Baseline Psychiatric History

US county-level variation in substance use disorder service utilization by insurance payers/self-pay

The Treatment of Menopausal Mood and Anxiety Disorders and The Role of Menopausal Hormone Therapy

Efficacy and Safety of a Single Dose of Psilocybin for Chronic Suicidal Ideation: Open-Label Trial

Maternal Mental Health Awareness Month: Postpartum Depression Risks

Maternal Mental Health Awareness Month: The Gap Between Identification and Care

The tyranny of the P-value...and what 20% risk reduction may actually mean for your patients

What Is Deprescribing? JCP's Deputy Editor In Chief explains.

Why Valproic Acid Should Be Avoided in Women of Reproductive Potential

Postpartum OCD: Intrusive Thoughts, Timing of Onset, and Infant Safety

Psychosocial Interventions and Functional Recovery in Schizophrenia: Implementation

Psychosocial Interventions and Functional Recovery in Schizophrenia: Drivers and Tools

Psychosocial Interventions and Functional Recovery in Schizophrenia: Video Abstract

It Takes Guts to Be Mentally Ill. Part 2: The Relationship Between the Gut Microbiota and Psychosis

It Takes Guts to Be Mentally Ill. Part 1: A Brief Overview of the Human Gut Microbiota

The Dopamine-3 Receptor in the Treatment of Schizophrenia: Part 2

The Dopamine-3 Receptor in the Treatment of Schizophrenia: Part 1

PsychCase360: Choosing the Right Long-Acting Injectable for Patients With Schizophrenia

The Near-Term Future of Muscarinic Agonists and Modulators for Schizophrenia: M1 and/or M4

Update on Current & Emerging Treatments for Negative Symptoms in Schizophrenia

Hypo- and Hyperactivity Symptoms Related to Norepinephrine Disturbances

The Role of Norepinephrine as a Common Treatment Target

What is the Role of the Muscarinic Receptor System in Schizophrenia?

Algorithms for TRD Treatment Success: Lessons from the Veterans Health Administration

Neurosteroids and Postpartum Depression

Interventional Neuropsychiatry

Overview of Norepinephrine Pathways and Modulation

The Role of Digital Phenotyping in Negative Symptoms Treatment Studies

Anticholinergic Burden in Schizophrenia

Prevalence and Determinants of Everyday Disability in Schizophrenia

Advanced Treatments, Limited Reach: Access in Interventional Psychiatry

PsychCase360: Balancing Psychiatric Stability and Cardiometabolic Health in Bipolar I Disorder

What are the Efficacy and Safety of Muscarinic Receptor Modulators in Patients With Schizophrenia?

What is the Place of Muscarinic Receptor Modulators in Clinical Care of Patients with Schizophrenia

The Case for Surgical Interventions in Treatment-Resistant Depression

Optimizing Recovery: Comprehensive Care Pathways for Depression

The Protective Effect of Clozapine on Suicide

5 Minute Pearls: Psychiatric Care Considerations for Sexually and Gender Diverse Populations

Impact of Tardive Dyskinesia on Patient Lives

Predictors for Initiation of Atypical LAIs in Individuals With Early-Phase Schizophrenia

Zuranolone in Major Depressive Disorder

5 Minute Pearls: Ketamine in Treatment Resistant Depression

Clozapine Considering Usage

Clozapine: Mitigating Side Effects

Clozapine: Weight Gain and Myocarditis Side Effects

Clozapine: Reasons To Use

Clozapine: History of use

Clozapine: Prescribing Hesitancy

Clozapine: When to Consider Its Use

Tardive Dyskinesia: Treatment

Tardive Dyskinesia: Risk Factors

Tardive Dyskinesia: Progression

Tardive Dyskinesia: Caregivers

Tardive Dyskinesia: History